R&D

Disrupting and accelerating drug discovery for faster and more accurate lead identification

Research shows 2-drug HIV regimen with comparable efficacy to 3-drug regimen

Novartis Kisqali® has received FDA approval to lower recurrence risk in patients with HR+/HER2-early breast cancer.

Bristol Myers Squibb’s Zeposia exhibits sustained safety and efficacy in Multiple sclerosis

Roche’s Xofluza reduces transmission of flu viruses, global trial shows

Novo Nordisk’s Wegovy® expects label update to include benefits in improving heart failure symptoms and physical function.

AstraZeneca’s Fasenra set to be approved for eosinophilic granulomatosis treatment

FDA approves drug with new pharmacological approach to schizophrenia treatment

AstraZeneca to pay up to $1.92 billion for potentially new lipid lowering molecule

GSK’s first-in-class antibiotic with new mechanism of action approved for priority review

Innovative subcutaneous combination therapy receives approval for Parkinson's disease

First once-daily subcutaneous prophylactic treatment for hemophilia recommended for European approval

Oral semaglutide shows reduction in risk of major adverse cardiovascular events in diabetic patients

AstraZeneca’s brand of benralizumab gains approval in Europe

GSK acquires new investigational therapy targeted for lupus treatment

Regeneron’s dupilumab has achieved approval in Europe as the first treatment approved for children with eosinophilic esophagitis

Anti-asthmatic therapy shows efficacy in treatment of chronic rhinosinusitis with nasal polyps

AbbVie’s emraclidine fails to demonstrate efficacy in management of schizophrenia

Selumetinib shows efficacy in adult patients with neurofibromatosis

Drug shows reduced risk of progression to type 2 diabetes in pre-diabetics

FDA accepts for review GSK’s new multiple myeloma therapy

AstraZeneca’s first in class therapy shows efficacy in metastatic prostate cancer

Injectable drug shows 99.9% efficacy in HIV prevention

National Cancer Institute Awards $2.5 Million Grant to Enhance Leukemia and Lymphoma Testing in Kenya

US FDA approves key antibiotic combination for treatment against resistant strains

FDA Grants Priority Review to Critical HIV Prevention Medication

Study shows Novo Nordisk’s combination drug achieves superior weight loss

Roche to pay up to $5.3 billion in development of new weight loss therapy

African Pharmaceutical Review.

African Pharmaceutical Review.

R&D

Disrupting and accelerating drug discovery for faster and more accurate lead identification

Research shows 2-drug HIV regimen with comparable efficacy to 3-drug regimen

Novartis Kisqali® has received FDA approval to lower recurrence risk in patients with HR+/HER2-early breast cancer.

Bristol Myers Squibb’s Zeposia exhibits sustained safety and efficacy in Multiple sclerosis

Roche’s Xofluza reduces transmission of flu viruses, global trial shows

Novo Nordisk’s Wegovy® expects label update to include benefits in improving heart failure symptoms and physical function.

AstraZeneca’s Fasenra set to be approved for eosinophilic granulomatosis treatment

FDA approves drug with new pharmacological approach to schizophrenia treatment

AstraZeneca to pay up to $1.92 billion for potentially new lipid lowering molecule

GSK’s first-in-class antibiotic with new mechanism of action approved for priority review

Innovative subcutaneous combination therapy receives approval for Parkinson's disease

First once-daily subcutaneous prophylactic treatment for hemophilia recommended for European approval

Oral semaglutide shows reduction in risk of major adverse cardiovascular events in diabetic patients

AstraZeneca’s brand of benralizumab gains approval in Europe

GSK acquires new investigational therapy targeted for lupus treatment

Regeneron’s dupilumab has achieved approval in Europe as the first treatment approved for children with eosinophilic esophagitis

Anti-asthmatic therapy shows efficacy in treatment of chronic rhinosinusitis with nasal polyps

AbbVie’s emraclidine fails to demonstrate efficacy in management of schizophrenia

Selumetinib shows efficacy in adult patients with neurofibromatosis

Drug shows reduced risk of progression to type 2 diabetes in pre-diabetics

FDA accepts for review GSK’s new multiple myeloma therapy

AstraZeneca’s first in class therapy shows efficacy in metastatic prostate cancer

Injectable drug shows 99.9% efficacy in HIV prevention

National Cancer Institute Awards $2.5 Million Grant to Enhance Leukemia and Lymphoma Testing in Kenya

US FDA approves key antibiotic combination for treatment against resistant strains

FDA Grants Priority Review to Critical HIV Prevention Medication

Study shows Novo Nordisk’s combination drug achieves superior weight loss

Roche to pay up to $5.3 billion in development of new weight loss therapy

African Pharmaceutical Review.

African Pharmaceutical Review.

R&D

Get Our Latest News & Update